.jpeg)
2026-07-16 07:21:04
This article summarizes adverse reactions associated with donidalorsen (DAWNZERA®) for prophylaxis of hereditary angioedema (HAE) attacks in patients aged 12 and older, including injection site reactions, upper respiratory tract infection, urinary tract infection, abdominal discomfort, hypersensitivity reactions, and monitoring of platelet/liver function, with safety notes for patients and clinicians.
2026-06-25 06:31:57
Tildrakizumab is a humanized monoclonal antibody targeting the IL-23 p19 subunit. This article reviews its efficacy in achieving high skin clearance rates (PASI 90/100), its favorable safety profile, convenient dosing schedule, and specific limitations regarding psoriatic arthritis and live vaccines.
2026-06-11 03:05:48
A detailed prescribing guide for Risankizumab (Skyrizi), covering indications for plaque psoriasis, psoriatic arthritis, and Crohn's disease, along with dosage schedules, infection risks, and storage instructions.
2026-06-04 04:33:17
This article provides detailed information on Ixekizumab (brand name Taltz), including its dosage forms and strengths, standard dosing regimens for psoriasis, psoriatic arthritis and Crohn's disease, injection techniques, storage conditions, missed dose management and treatment duration recommendations, offering comprehensive reference for patients and healthcare providers.
2026-05-29 07:43:00
An in-depth analysis of the core differences between Risankizumab (p19 inhibitor) and Ustekinumab (p40 inhibitor) in target mechanisms, efficacy in psoriasis and Crohn's disease, dosing frequency, and safety profiles.
2026-05-25 04:15:46
Can topical Delgocitinib (JAK inhibitor) restore skin pigment? Explore the science behind repigmentation, current clinical trial status, and global access for vitiligo patients.
2026-05-22 03:58:23
KOSELUGO® (Selumetinib), a highly selective MEK inhibitor, is now approved for pediatric and adult patients with symptomatic, inoperable plexiform neurofibromas (PN) associated with Neurofibromatosis Type 1 (NF1). This article explores the clinical challenges, dosing strategies, and global market dynamics of this breakthrough targeted therapy.
2026-04-28 04:12:36
This article details the approved indications and mechanism of action of sopyrronium bromide (brand name Sofdra), an anticholinergic medication, focusing on the core reasons why it is not recommended for facial hyperhidrosis, relevant safety precautions, and alternative treatment options.
2026-04-21 02:42:40
Icotyde (generic name: Icotrokinra) is a medication that works by modulating the immune system. It has a relatively mild overall side effect profile, but still requires close monitoring of drug reactions by patients and healthcare providers. This article details its common side effects and targeted mitigation strategies, core pharmacokinetic characteristics, and standard drug storage requirements.
2026-04-03 06:57:16
Deucravacitinib (brand name Sotyktu, Chinese trade name Songdiduo) is a next-generation, oral, highly selective TYK2 inhibitor developed for the pathological mechanism of psoriasis. Approved in multiple countries and regions worldwide for the systemic treatment of adults with moderate-to-severe plaque psoriasis, it precisely modulates inflammatory pathways to improve skin lesions, with the advantages of rapid onset, durable long-term efficacy, and convenient oral administration, providing a non-injectable, non-biologic treatment option for patients with psoriasis.
2026-03-18 05:32:12
Apremilast is an oral small-molecule PDE4 inhibitor used to treat psoriasis, psoriatic arthritis and Behcet's disease. This article explains its mechanism, efficacy and safety.
2026-03-12 03:31:19
Remibrutinib (brand name Ruipoduo) is a highly selective Bruton's tyrosine kinase (BTK) inhibitor for chronic spontaneous urticaria. Clinical studies show good safety and tolerability, with common side effects including headache and gastrointestinal reactions. Infection prevention, hematological monitoring, and long-term follow-up are key.
